Infant respiratory syncytial virus prophylaxis and nasopharyngeal microbiota until 6 years of life: a subanalysis of the MAKI randomised controlled trial
Subanalysis found palivizumab in otherwise healthy preterm infants is associated with persistent effects on the abundance of specific, potentially pathogenic, microbial taxa in the respiratory tract. Several species were associated with reversible airway obstruction at 6 years.
Source:
The Lancet Respiratory Medicine
SPS commentary:
A related commentary states that clinical trials are in progress to provide an ideal opportunity to gain an improved understanding of the mechanisms that contribute to acute and long-term RSV respiratory morbidity.